Repligen | RGEN - 销售和管理费用

金融业

USD

USD 2.93B

现金及等价物

USD 582.65M

USD 85.97M

USD 1.16B

USD 126.21M

USD 546.59M

USD 19.98M

USD 40.01M

1.78K

EPS每股收益

USD 0.48

股本和储备

USD 2.11B

USD 108.28M

债务利息支出

USD 5.58M

USD 7.31M

USD 546.59M

USD 7.44B

USD 8.33M

USD 174.27M

USD 19.98M

普通股股本

USD 56.4M

109.48

USD 19.11M

USD 194M

销售和管理费用

USD 76.54M

USD 179.26M

贸易债权人

USD 34.66M

应收帐款人

USD 151.55M

	销售和管理费用	更改		日
Agilent	USD 465M		11M	2026-03
Align Technology	USD 465.34M		23.67M	2026-03
Bio Techne	USD 109.34M		4.35M	2026-03
BioMarin Pharmaceutical	USD 258.28M		63.92M	2026-03
Bristol-Myers Squibb	USD 1.62B		564M	2026-03
Bruker	USD 242.1M		5.1M	2026-03
Charles River Laboratories	USD 159.42M		36.71M	2026-03
Danaher	USD 1.86B		166M	2026-03
Dentsply International	USD 351M		32M	2026-03
General Electric Aerospace	USD 1.08B		496M	2026-03
Henry Schein	USD 809M		1000K	2026-03
Illumina	USD 272M		11M	2026-03
IQVIA Holdings	USD 502M		34M	2026-03
Mettler Toledo International	USD 258.33M		1.5M	2026-03
Myriad Genetics	USD 122.3M		6.7M	2025-12
OraSure Technologies	USD 13.21M		3.29M	2025-12
Pacific Biosciences Of California	USD 37.24M		25.68M	2025-12
Pfizer	USD 2.92B		1.16B	2026-03
Repligen	USD 76.54M		2.17M	2026-03
Revvity	USD 253.88M		2.15M	2026-03
Standard Biotools	USD 21.55M		5.05M	2025-12
Thermo Fisher Scientific	USD 1.8B		179M	2026-03
Waters	USD 394M		153.99M	2026-03
West Pharmaceutical Services	USD 99.5M		7M	2026-03